Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
(Suzhou, China) July 31, 2013-Crystal Pharmatech, a leading contract research organization (CRO) for solid-state research of active pharmaceutical ingredients and formulations, will partner with American Chemical Society’s ACS Prospectives to co-sponsor the International Symposium on Pharmaceutical Solid-State Research. A year in development, the symposium will take place at the Grand Hotel Dushlake in Suzhou, China, October 17-19 with Dr. Elizabeth B. Vadas, Ph.D., InSciTech Inc., chairing the symposium. The agenda, which focuses on understanding of the properties of new chemical entities as they relate to the solid state, also addresses relevant and emerging topics such as fundamentals of amorphous materials, the development of polymer stabilized amorphous solid dispersions, particle engineering and the control of crystallization. Industry examples of innovative formulation approaches will be a cornerstone of the conference: http://crystalpharmatech.com/
A distinguished panel of scientists and researchers in drug development will moderate panel discussions, present compelling information and research and explore cutting-edge scientific and innovative approaches, all of which can and will impact development of API’s and dosage forms. Joining Dr. Jian Wang, Ph.D. of Crystal Pharmatech are Prof. Bill Jones of Cambridge University and Prof. Robert Young with Simon Fraser University, as well as scientists from Bristol Myers Squibb, Corealis Pharma, Biogen Idec, among others.
The conference is geared to specialists interested in the development and evaluation of API’s and pharmaceutical products, including scientists, engineers, formulators, manufacturers, regulators, managers and key decision makers will be attending the symposium.
Crystal Pharmatech, headquartered in Suzhou, China with a US business office in Princeton, NJ, is a technology-driven CRO that offers materials research services for active pharmaceutical ingredients and formulations used in the drug discovery process. As a preferred provider among innovator pharmaceutical companies such as Amgen and Agios, in addition to the industry’s biggest companies, Crystal Pharmatech has extensive experience selecting the appropriate solid phase of a wide range of compounds. It provides its customers with data derived from experiments and also partners with clients to ensure comprehensive solutions for their research needs using solid-state research, crystallization process development based on sound scientific understanding.
Isabelle
Isabelle Kellogg
Kellogg & Partners
NY | Paris | LA
M: 917 361 2866
www.ikellogg.com
Help employers find you! Check out all the jobs and post your resume.
